Helen Nadel, MD, FRCPC, on Imperatives for Nuclear Medicine and Molecular Imaging
Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.
Nuclear medicine, like many subspecialties, is facing a workforce crisis. The lack of incoming residents, techs, researchers, and other medical staff is hitting at a particularly poor time, as the role of nuclear medicine and molecular imaging is rapidly expanding with newfound applications in oncology, neurodegenerative disorders, and beyond.
The lack of staffing is top of mind for the Society of Nuclear Medicine and Molecular Imaging's incoming president Helen Nadel, MD, FRCPC, who began her year-long term at this year's SNMMI Annual Meeting, taking place June 24-27, 2023 in Chicago.
Dr. Nadel, who is director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at Stanford and clinical professor of radiology at the Stanford School of Medicine, told Diagnostic Imaging that recruitment efforts are in full effect, with targeted programs being rolled out that focus on early education opportunities. For instance, the society held an information fair for interested high school students during the annual meeting, where children and their parents were welcome to tour exhibits and learn more about the specialty.
Dr. Nadel and other SNMMI leadership are also focused on boosting the profile of nuclear medicine, molecular imaging, and theranostics globally by partnering with other organizations and associations in the space to produce best practice guidelines and appropriate use critieria.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
